

Ribziff DSR Capsule

**Domperidone (30 mg) + Rabeprazole (20 mg)
Capsule**

Description:

Domperidone (30 mg) + Rabeprazole (20 mg) capsule is a combination medication that includes Domperidone, a prokinetic agent, and Rabeprazole, a proton pump inhibitor (PPI). This combination is designed to provide relief from symptoms associated with gastrointestinal disorders like acid reflux, GERD (Gastroesophageal Reflux Disease), gastritis, and gastroparesis (delayed gastric emptying).

Composition:

- Domperidone: 30 mg
 - Rabeprazole: 20 mg
-

Indications:

This combination capsule is indicated for the following conditions:

1. **Gastroesophageal Reflux Disease (GERD):**
 - For relief from heartburn, acid regurgitation, and other symptoms of GERD.
2. **Gastritis:**
 - Helps manage gastritis, especially when associated with acid hypersecretion.
3. **Gastroparesis:**
 - For the treatment of delayed gastric emptying (gastroparesis),

which can cause symptoms like nausea, vomiting, and bloating.

4. Peptic Ulcer Disease:

- For the management of peptic ulcers and the prevention of ulcer recurrence by reducing gastric acid and improving stomach motility.
-

Mechanism of Action:

- **Domperidone (30 mg):**
Domperidone is a dopamine antagonist that enhances gastric motility and accelerates gastric emptying. It also reduces nausea and vomiting by blocking dopamine receptors in the gut, facilitating smoother digestion and reducing symptoms like bloating and fullness.
 - **Rabeprazole (20 mg):**
Rabeprazole is a proton pump inhibitor (PPI) that inhibits the H⁺/K⁺ ATPase pump in the parietal cells of the stomach, thereby significantly reducing the production of gastric acid.
-

Dosage and Administration:

- **Adults:**
 - Take 1 capsule (30 mg Domperidone + 20 mg Rabeprazole) once daily, preferably before a meal or as directed by your healthcare provider.
 - The dosage may be adjusted based on the severity of symptoms and individual response.
- **Children:**

- This combination capsule is typically not recommended for use in children unless specifically prescribed by a healthcare provider, as the dosage will need to be adjusted according to the child's condition and weight.

Note:

- Follow the prescribed dosage and schedule strictly. Do not exceed the recommended dose without consulting your doctor.

Side Effects:

- **Common:**
 - Abdominal discomfort, nausea, headache, and dizziness.
 - Dry mouth, diarrhea, or constipation.
 - Bloating or flatulence.
- **Serious but Rare:**
 - **Cardiovascular effects:** Domperidone has been associated with an increased risk of QT prolongation and arrhythmias, particularly in patients with underlying heart conditions.
 - **Liver toxicity:** Symptoms of liver dysfunction like jaundice (yellowing of the skin or eyes), dark urine, or unusual fatigue (rare with Rabeprazole).

Precautions:

- 1. Cardiovascular Conditions:**
 - Use with caution in patients with a history of heart conditions, such as arrhythmias or QT prolongation, as Domperidone may increase the risk of these conditions.
- 2. Liver Impairment:**

- Rabeprazole should be used cautiously in patients with liver disease as its metabolism may be affected.

3. Renal Impairment:

- Patients with severe renal impairment may require dose adjustments, especially with Domperidone, as it is primarily excreted through the kidneys.

4. Pregnancy and Breastfeeding:

- **Pregnancy:** This medication should only be used during pregnancy if clearly needed and prescribed by a healthcare provider.

5. Long-term Use:

- Long-term use of Rabeprazole may increase the risk of vitamin B12 deficiency, bone fractures, and gastrointestinal infections.

Storage:

- Store at room temperature (15-30°C), away from light and moisture.
- Keep the capsule bottle tightly closed and out of reach of children.
- Do not use the medication if the packaging is damaged or if the expiration date has passed.

Note:

For best results, take this medication as directed, and do not miss doses.

Manufactured in India for:

CafoliTM
L I F E C A R E

Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for